Underwriting AgreementUnderwriting Agreement • July 17th, 2015 • Vermillion, Inc. • In vitro & in vivo diagnostic substances • New York
Vermillion, Inc., a Delaware corporation (the “Company”), confirms its agreement pursuant to this Underwriting Agreement (this “Agreement”) to the several underwriters listed on Schedule A attached hereto (collectively, the “Underwriters”), for whom Canaccord Genuity Inc. is acting as representative (in such capacity, the “Representative”), with respect to the issue and sale by the Company of an aggregate total of 8,350,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”), the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Firm Shares set forth in Schedule A hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 1 hereof to purchase all or any part of 1,252,500 additional shares of Common Stock to cover over-allotments, if any. The Firm Shares and all or any part of the 1,252,500 shares of Common Stock subje
